1Sapoznikov B, Villin A. Minidose aspirin and gastrointestinal bleed - ing : A retrospective, ease - control study in hospitalized patients [J]. Dig Dis Sei,2005,50(9) :1621 -1624.
3anas A, Perez - Aisa MA, Feu F, et al. A nationwide study of mor - tality associated with hospital admission due to severe gastrointesti -nal events and those associated with nonstemidal antiinflammatory drug use [ J ]. Am J Gastroentero1,2005,100 (8) : 1685 - 1693.
6Loll PJ, Picot D, Garavito RM, et al. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglan - din H ,synthase[ J]. Nat Struct Biol, 1995,2 ( 8 ) : 637 - 643.
6[4]American Rheumatism Association (ARA) Glossary Committee[M]. Dictionary of the Rheumatic Diseases, Vol.1: Signs and Symptoms. New York, NY, Contact Associates International, 1998.
7[5]Cannon G,Caldwell J,Holt P,et al. MK-0966,a specific COX-2 inhibitor,has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis(OA) in a 26-week controlled clinical trial [abstract no. 983][J]. Arthritis Rheum, 1998, 41 Suppl:S196.
8[6]Truitt K, Ettinger W, Schnitzer T, et al. Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients 80 years and older[abstract no. 895]. In: XIV European League Against Rheumatism Congress, 1999, 6-11:Glasgow.
9Seheiman, Tillner A, Pohi T, et al. Reduction of non-steroidol anti-inflammafory drug induced gastric injury and leueoryte endothelial adhlsion by octreotide [J]. Gut, 1997, 40: 720.
